Novo Nordisk A/S (NOVO:CA) Discusses Obesity and Diabetes Portfolio Progress and Pill Launch Milestones at R&D Event June 7, 2026 7:30 PM EDT
Company Participants
Michael Novod – Senior VP & Head of Investor Relations
Maziar Doustdar – President, CEO & Member of the Management Board
Martin Lange – EVP of R&D, Chief Scientific Officer and Member of the Management Board
Karsten Knudsen – Executive VP, CFO & Member of the Management Board
Conference Call Participants
Richard Vosser – JPMorgan Chase & Co, Research Division
Martin Parkhoi – SEB, Research Division
Seamus Fernandez – Guggenheim Securities, LLC, Research Division
Peter Verdult – BNP Paribas, Research Division
James Gordon – Barclays Bank PLC, Research Division
James Quigley – Goldman Sachs Group, Inc., Research Division
Simon Baker – Rothschild & Co Redburn, Research Division
Michael Nedelcovych – TD Cowen, Research Division
Benjamin Jackson – Jefferies LLC, Research Division
Presentation
Michael Novod
Senior VP & Head of Investor Relations
All right. Good evening, and welcome to the 2026 Novo Nordisk Investor Event in connection with the American Diabetes Association’s Annual Meeting here in New Orleans. So my name is Michael Novod. I’m heading up the IR team at Novo. And I’m just going to run through a bit of practicalities — apparently not. I just want to throw a bit of a practicality. So we’re going to start with having a short presentation and then also followed by Q&A. And then the event is going to have a duration of 50 minutes before we’re going to conclude. And with — all right, I should also say that we do expect to make forward-looking statements, and they may differ from expectations. So read that just as a reminder. Today’s speakers on the stage is our CEO, Mike Doustdar, he’s going to give some brief introduction and is also Martin Holst Lange, Executive Vice President, Head of Research and Development; and also Chief Scientific Officer; and then also for the Q&A will also be joined by Karsten Munk
